Účinnost 24týdenní léčby peginterferonem alfa-2b plus ribavirinem u pacientů s chronickou hepatitidou typu C infikovaných genotypem 1 a s mírnou virémií před léčbou

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F06%3A00001408" target="_blank" >RIV/00023001:_____/06:00001408 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

Popis výsledku v původním jazyce

Background/Aims Previous studies using standard interferon and ribavirin combination therapy suggested that patients infected with HCV-1 and a low pretreatment HCV-RNA level can be treated for 24 weeks without compromising sustained virologic response rates. The aim of the present study was to investigate this schedule in the era of pegylated interferon- plus ribavirin. Methods Patients chronically infected with HCV-1 (n=235) and a screening viremia &#8804;600,000 IU/mL (real-time PCR) were treated withpeginterferon alfa-2b 1.5 &#956;g/kg subcutaneously once weekly plus ribavirin 800-1400 mg/day based on body weight for 24 weeks. Results End-of-treatment and sustained virologic response rates were 80 and 50%, respectively. The 48-week historical control (Manns et al., Lancet 2001;358:958-65) had similar end-of-treatment (74%) but higher sustained virologic response rates (71%). This difference was due to a high virologic relapse rate after 24 weeks of therapy (37%) compared with the

Název v anglickém jazyce

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

Popis výsledku anglicky

Background/Aims Previous studies using standard interferon and ribavirin combination therapy suggested that patients infected with HCV-1 and a low pretreatment HCV-RNA level can be treated for 24 weeks without compromising sustained virologic response rates. The aim of the present study was to investigate this schedule in the era of pegylated interferon- plus ribavirin. Methods Patients chronically infected with HCV-1 (n=235) and a screening viremia &#8804;600,000 IU/mL (real-time PCR) were treated withpeginterferon alfa-2b 1.5 &#956;g/kg subcutaneously once weekly plus ribavirin 800-1400 mg/day based on body weight for 24 weeks. Results End-of-treatment and sustained virologic response rates were 80 and 50%, respectively. The 48-week historical control (Manns et al., Lancet 2001;358:958-65) had similar end-of-treatment (74%) but higher sustained virologic response rates (71%). This difference was due to a high virologic relapse rate after 24 weeks of therapy (37%) compared with the

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2006

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Hepatology

ISSN

0168-8278

e-ISSN

—

Svazek periodika

44

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

97-103

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—